The Europe Automated Cell Counting Market would witness market growth of 11.8% CAGR during the forecast period (2023-2030).
A confluence of factors drives the exponential growth of the market. Research laboratories, biotechnology firms, pharmaceutical companies, academic institutions, and healthcare facilities increasingly rely on these instruments to meet the escalating demand for precise, high-throughput cell analysis. The constant need for accuracy in cellular quantification, viability assessment, and morphological characterization fuels the market's expansion. The evolving medical research and diagnostics landscape has propelled these instruments to the forefront.
Automated cell counting instruments are integral in various research fields, including immunology, oncology, stem cell research, drug discovery, and infectious diseases. These instruments are critical in analyzing blood cells and diagnosing haematological disorders in clinical diagnostics. The emergence of cell-based therapies and regenerative medicine drives the demand for precise and reliable cell-counting technologies. This is essential for quality control, assessing cell viability, and ensuring the effectiveness of cell-based therapies.
Healthcare expansion leads to increased availability of medical facilities, which drives the demand for advanced diagnostic tools like instruments for accurate and efficient diagnoses. Improved healthcare accessibility brings the need for efficient diagnostic technologies to various healthcare settings, increasing the adoption of these instruments in clinics, hospitals, and laboratories. Consequently, the expansion of the healthcare sector in the region and the increasing demand for medical technologies and equipment are factors propelling the expansion of the market.
The Germany market dominated the Europe Automated Cell Counting Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $539.1 million by 2030. The UK market is exhibiting a CAGR of 10.8% during (2023 - 2030). Additionally, The France market would experience a CAGR of 12.7% during (2023 - 2030).
Based on Product, the market is segmented into Consumables Accessories, and Instruments (Image-based Cell Counters, Flow Cytometers, Electrical Impendence Coulter Counters). Based on Application, the market is segmented into Cell Line development, Blood Analysis, Stem Cell Research, and Others. Based on End-use, the market is segmented into Pharmaceutical Biotechnology Companies, Hospitals Diagnostic laboratories, Research Academic Institutes, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Shanghai Ruiyu Biotechnology Co., Ltd. (Alit Biotech (Shanghai) Co., Ltd.), Thermo Fisher Scientific, Inc., Bio-Rad laboratories, Inc., F. Hoffmann-La Roche Ltd., Danaher Corporation, Olympus Corporation, Merck KGaA, Abbott Laboratories, Sysmex Corporation, and Agilent Technologies, Inc.
A confluence of factors drives the exponential growth of the market. Research laboratories, biotechnology firms, pharmaceutical companies, academic institutions, and healthcare facilities increasingly rely on these instruments to meet the escalating demand for precise, high-throughput cell analysis. The constant need for accuracy in cellular quantification, viability assessment, and morphological characterization fuels the market's expansion. The evolving medical research and diagnostics landscape has propelled these instruments to the forefront.
Automated cell counting instruments are integral in various research fields, including immunology, oncology, stem cell research, drug discovery, and infectious diseases. These instruments are critical in analyzing blood cells and diagnosing haematological disorders in clinical diagnostics. The emergence of cell-based therapies and regenerative medicine drives the demand for precise and reliable cell-counting technologies. This is essential for quality control, assessing cell viability, and ensuring the effectiveness of cell-based therapies.
Healthcare expansion leads to increased availability of medical facilities, which drives the demand for advanced diagnostic tools like instruments for accurate and efficient diagnoses. Improved healthcare accessibility brings the need for efficient diagnostic technologies to various healthcare settings, increasing the adoption of these instruments in clinics, hospitals, and laboratories. Consequently, the expansion of the healthcare sector in the region and the increasing demand for medical technologies and equipment are factors propelling the expansion of the market.
The Germany market dominated the Europe Automated Cell Counting Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $539.1 million by 2030. The UK market is exhibiting a CAGR of 10.8% during (2023 - 2030). Additionally, The France market would experience a CAGR of 12.7% during (2023 - 2030).
Based on Product, the market is segmented into Consumables Accessories, and Instruments (Image-based Cell Counters, Flow Cytometers, Electrical Impendence Coulter Counters). Based on Application, the market is segmented into Cell Line development, Blood Analysis, Stem Cell Research, and Others. Based on End-use, the market is segmented into Pharmaceutical Biotechnology Companies, Hospitals Diagnostic laboratories, Research Academic Institutes, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Shanghai Ruiyu Biotechnology Co., Ltd. (Alit Biotech (Shanghai) Co., Ltd.), Thermo Fisher Scientific, Inc., Bio-Rad laboratories, Inc., F. Hoffmann-La Roche Ltd., Danaher Corporation, Olympus Corporation, Merck KGaA, Abbott Laboratories, Sysmex Corporation, and Agilent Technologies, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Consumables Accessories
- Instruments
- Image-based Cell Counters
- Flow Cytometers
- Electrical Impendence Coulter Counters
By Application
- Cell Line development
- Blood Analysis
- Stem Cell Research
- Others
By End-use
- Pharmaceutical Biotechnology Companies
- Hospitals Diagnostic laboratories
- Research Academic Institutes
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Shanghai Ruiyu Biotechnology Co., Ltd. (Alit Biotech (Shanghai) Co., Ltd.)
- Thermo Fisher Scientific, Inc.
- Bio-Rad laboratories, Inc.
- F.Hoffmann-La Roche Ltd.
- Danaher Corporation
- Olympus Corporation
- Merck KGaA
- Abbott Laboratories
- Sysmex Corporation
- Agilent Technologies, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Europe Automated Cell Counting Market by Product
Chapter 6. Europe Automated Cell Counting Market by Application
Chapter 7. Europe Automated Cell Counting Market by End-use
Chapter 8. Europe Automated Cell Counting Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Shanghai Ruiyu Biotechnology Co., Ltd. (Alit Biotech (Shanghai) Co., Ltd.)
- Thermo Fisher Scientific, Inc.
- Bio-Rad laboratories, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Olympus Corporation
- Merck KGaA
- Abbott Laboratories
- Sysmex Corporation
- Agilent Technologies, Inc.
Methodology
LOADING...
